Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEED: Imiglucerase in Chinese Patients with Gaucher Disease Type III
NCT04656600Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of beta-glucocerebrosidase in Gaucher disease type 3, sponsored by Sanofi. Started Mar 2021; status: completed.
02
Drugs
beta-glucocerebrosidase
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT04656600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656600.